Research programme: cancer therapeutics - Abraxis BioScience

Alternative Names: ABI-013; ABI-139; nab^®-ABI-139; nab^®-CY196

Latest Information Update: 04 Nov 2017

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abraxis BioScience
Developer Celgene Corporation
Class Albumins; Antisense oligonucleotides; Taxanes
Mechanism of Action Antisense RNA inhibitors; HSP90 heat-shock protein inhibitors; Tubulin modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
16 Oct 2010 Abraxis BioScience has been acquired by Celgene Corporation
30 Jun 2010 Celgene Corporation to acquire Abraxis BioScience

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com